Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 15, 2026European Heart Journal Supplements

Use of Vericiguat in the VICTOR Trial: A Study That Is Difficult to Interpret

View Full Paper
Ask AI
Bookmark
Share

Authors

FOFrancesco OrsoCBChristian Basile

Discussion

Loading...

Member takes

Overview

VICTOR trial reveals no composite endpoint reduction in clinically stable heart failure patients, highlighting vericiguat's role in mortality.

Key Points

  • To explore the efficacy of vericiguat in clinically stable patients with heart failure receiving optimal medical therapy.
  • Analysis of the VICTOR trial results focusing on the primary composite endpoint.
  • Assessment of hospitalizations and mortality rates in patients with heart failure.
  • Evaluation of treatment effects in a lower-risk patient population.
  • No significant reduction in the primary composite endpoint of cardiovascular death and hospitalization for heart failure.
  • Significant reductions in both cardiovascular and all-cause mortality were observed.
  • The findings contrast with expectations based on earlier trials in patients with HFrEF.

Cite This Study

Orso et al. (2026) studied this question.

synapsesocial.com/papers/69b5ff3b83145bc643d1b6abhttps://doi.org/10.1093/eurheartjsupp/suag044
View Full Paper
Ask AI
Bookmark
Share